-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Orchard Therapeutics plc (NASDAQ:ORTX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Orchard Therapeutics plc (NASDAQ:ORTX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
It's been a good week for Orchard Therapeutics plc (NASDAQ:ORTX) shareholders, because the company has just released its latest second-quarter results, and the shares gained 8.9% to US$0.58. Revenues of US$4.4m crushed expectations, although expenses also blew out, with the company reporting a statutory loss per share of US$0.40, 55% bigger than analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Check out our latest analysis for Orchard Therapeutics
NasdaqGS:ORTX Earnings and Revenue Growth August 7th 2022After the latest results, the six analysts covering Orchard Therapeutics are now predicting revenues of US$17.7m in 2022. If met, this would reflect a huge 53% improvement in sales compared to the last 12 months. Losses are forecast to narrow 8.4% to US$1.22 per share. Before this latest report, the consensus had been expecting revenues of US$16.9m and US$0.96 per share in losses. So it's pretty clear the analysts have mixed opinions on Orchard Therapeutics even after this update; although they upped their revenue numbers, it came at the cost of a sizeable expansion in per-share losses.
The consensus price target stayed unchanged at US$4.20, seeming to suggest that higher forecast losses are not expected to have a long term impact on the valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Orchard Therapeutics, with the most bullish analyst valuing it at US$5.00 and the most bearish at US$1.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that Orchard Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 135% annualised revenue growth to the end of 2022 noticeably faster than its historical growth of 44% p.a. over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 14% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Orchard Therapeutics to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts increased their loss per share estimates for next year. Happily, they also upgraded their revenue estimates, and are forecasting revenues to grow faster than the wider industry. The consensus price target held steady at US$4.20, with the latest estimates not enough to have an impact on their price targets.
With that in mind, we wouldn't be too quick to come to a conclusion on Orchard Therapeutics. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Orchard Therapeutics analysts - going out to 2024, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 2 warning signs for Orchard Therapeutics you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
这是很好的一周果园治疗公司(纳斯达克股票代码:ORTX)股东,因为该公司刚刚发布了最新的第二季度业绩,该股上涨8.9%,至0.58美元。440万美元的收入超出了预期,尽管支出也出现了井喷,该公司报告的法定每股亏损为0.40美元,比分析师预期高出55%。在业绩公布后,分析师们更新了他们的收益模型,如果他们认为公司的前景发生了巨大变化,还是一切照旧,那将是一件好事。考虑到这一点,我们收集了最新的法定预测,看看分析师对明年的预期是什么。
查看我们对Orchard Treeutics的最新分析
纳斯达克:ORTX收益和收入增长2022年8月7日在公布最新业绩后,负责Orchard Treeutics的六位分析师现在预测,2022年的收入将达到1770万美元。如果得到满足,这将反映出与过去12个月相比,销售额大幅提高了53%。预计亏损将收窄8.4%,至每股1.22美元。在这份最新报告发布之前,市场的普遍预期是营收为1690万美元,每股亏损0.96美元。因此,很明显,即使在这次更新之后,分析师们对Orchard Treeutics的看法也是褒贬不一的;尽管他们提高了收入数字,但这是以每股亏损大幅扩大为代价的。
共识目标价维持在4.20美元不变,似乎表明较高的预期亏损预计不会对估值产生长期影响。不过,还有另一种方式来考虑价格目标,那就是看看分析师提出的价格目标的范围,因为广泛的估计可能表明,对企业可能出现的结果有不同的看法。对Orchard Treeutics有一些不同的看法,最乐观的分析师对其估值为5.00美元,最悲观的分析师估值为每股1.00美元。这是一个相当广泛的估计价差,表明分析师们预测了该业务可能出现的各种结果。
现在看一看更大的图景,我们可以理解这些预测的方法之一是看看它们与过去的业绩和行业增长估计如何比较。从最新的估计中可以清楚地看到,Orchard Treeutics的增长率预计将大幅加快,截至2022年底的预期年化收入增长135%,明显快于其历史上44%的年增长率。在过去三年里。相比之下,我们的数据显示,类似行业的其他公司(有分析师覆盖)的收入预计将以每年14%的速度增长。显然,虽然增长前景比最近的过去更光明,但分析师也预计Orchard Treeutics的增长速度将快于整个行业。
底线
最重要的是,分析师们上调了对明年每股亏损的预期。令人高兴的是,他们还上调了营收预期,并预计营收增长速度将快于整个行业。共识价格目标持稳于4.20美元,最新估计不足以对他们的价格目标产生影响。
考虑到这一点,我们不会太快得出关于果园治疗的结论。长期盈利能力比明年的利润重要得多。我们有来自多个Orchard Treeutics分析师的估计-到2024年,你可以在我们的平台上免费看到它们。
不过,你应该始终考虑风险。举个例子,我们发现果园疗法的2个警示标志你应该意识到。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧